Placebo Matching Mitapivat

Phase 3

Placebo Matching Mitapivat is one of 2 therapeutic programs targeting Transfusion-dependent Alpha-Thalassemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Transfusion-Dependent Alpha-ThalassemiaActive, not recruiting

Non-Transfusion-Dependent Alpha-ThalassemiaActive, not recruiting

Transfusion-Dependent Alpha-ThalassemiaPhase 3

Active, not recruiting

Non-Transfusion-Dependent Alpha-ThalassemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Transfusion-Dependent Alpha-Thalassemia

#DrugCompanyPhaseTrials

Aqvesme

AAgios Pharmaceuticals, Inc.

Phase 3

2 2

Placebo Matching Mitapivat

AAgios Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Non-Transfusion-Dependent Alpha-Thalassemia

NCT04770753

Q2 2029

Phase 3Active, not recruiting

Transfusion-Dependent Alpha-Thalassemia

NCT04770779

Q1 2032

Phase 3Not yet recruiting

Non-Transfusion-Dependent Alpha-Thalassemia

NCT07517133

Clinical

Trials by Indication[1]

Non-Transfusion-dependent Alpha-Thalassemia2 trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Non-Transfusion-Dependent Thalassemia

Not yet recruiting·AAgios Pharmaceuticals, Inc.·Phase 3·NCT07517133·45 enrolled

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)

Active, not recruiting·AAgios Pharmaceuticals, Inc.·Phase 3·NCT04770753·194 enrolled

Transfusion-dependent Alpha-Thalassemia1 trial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)

Active, not recruiting·AAgios Pharmaceuticals, Inc.·Phase 3·NCT04770779·258 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Placebo Matching Mitapivat. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo Matching Mitapivat. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Agios Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAgios Pharmaceuticals, Inc.

Placebo Matching Mitapivat

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Q1 2032

Trials by Indication[1]

Non-Transfusion-dependent Alpha-Thalassemia2 trials

Transfusion-dependent Alpha-Thalassemia1 trial

References

Drug Info

Quick Facts

Related News